{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:09:25Z","timestamp":1785431365592,"version":"3.56.0"},"reference-count":12,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032682","name":"Department of Clinical Biochemistry, Aarhus University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032682","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/040r8fr65","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: PEG-Asparaginase and Erwinia asparaginase are enzyme-based anticancer therapies used in the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL), where adequate plasma enzyme activity is required for therapeutic efficacy. In many study groups, therapeutic drug monitoring is routinely applied due to pharmacokinetic variability and the risk of hypersensitivity reactions followed by increased clearance and insufficient treatment. In clinical practice, samples may be exposed to prolonged transport and variable pre-analytical conditions. Knowledge on pre-analytical stability is important for correct interpretation of PEG-Asparaginase and Erwinia asparaginase activity in plasma. This study aimed to evaluate the in vitro stability of PEG-Asparaginase and Erwinia asparaginase under pre-analytical conditions. Methods: Three experimental stability studies were conducted at two activity levels. Enzyme stability in plasma was assessed during storage at 4 \u00b0C and 20 \u00b0C for up to 14 days and following three freeze\u2013thaw cycles. Stability in whole blood prior to centrifugation was evaluated over 24 h. Enzyme activity was measured using a validated spectrophotometric assay, and stability was defined as a deviation within \u00b115% of baseline activity. Results: Both enzymes remained stable in plasma for up to 14 days at 4 \u00b0C and 20 \u00b0C, and no clinically relevant reduction in enzyme activity of freeze\u2013thaw cycling was observed. In whole blood, Erwinia asparaginase and high-activity PEG-Asparaginase remained stable for 24 h at 20 \u00b0C, whereas low-activity PEG-Asparaginase showed a reduction in activity of approximately 22%, mainly within the first two hours. Conclusions: PEG-Asparaginase and Erwinia asparaginase are stable in plasma for up to 14 days at room temperature, enabling shipment of plasma samples by mail. However, prompt centrifugation is recommended for samples with low PEG-Asparaginase activity to ensure accurate therapeutic drug monitoring.<\/jats:p>","DOI":"10.3390\/pharmaceutics18050618","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:39:34Z","timestamp":1779295174000},"page":"618","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of PEG-Asparaginase and Erwinia Asparaginase Activity Under Variable Storage Conditions"],"prefix":"10.3390","volume":"18","author":[{"given":"S\u00f8ren Aleksander","family":"Friederici Dahl","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Randers Regional Hospital, 8930 Randers, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-0140","authenticated-orcid":false,"given":"Elke","family":"Hoffmann-L\u00fccke","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3902-3694","authenticated-orcid":false,"given":"Birgitte","family":"Klug Albertsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark"},{"name":"Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, 8200 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0417-1195","authenticated-orcid":false,"given":"Eva","family":"Greibe","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"ref_2","first-page":"241","article-title":"Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia","volume":"1","author":"Avramis","year":"2006","journal-title":"Int. J. Nanomed."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1080\/10428194.2018.1542146","article-title":"Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children\u2019s Oncology Group AALL07P4","volume":"60","author":"Schore","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.2020006583","article-title":"Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia","volume":"137","author":"Grell","year":"2021","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children\u2019s Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_6","unstructured":"European Medicines Agency (2021). Guidelines for Real-Time Therapeutic Drug Monitoring (TDM) of Asparaginase. European Union Drug Regulating Authorities Clinical Trials Database (EudraCT), European Medicines Agency. Report No.: 2018-001795\u201338."},{"key":"ref_7","unstructured":"European Medicines Agency A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (1\u201345 years of age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL) [Internet]. European Union Drug Regulating Authorities Clinical Trials Database (EudraCT). Report No.: 2018-001795\u201338. Available online: https:\/\/dapho.dk\/wp-content\/uploads\/2023\/05\/akut-lymfoblastisk-leukaemi-alltogether.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0003-2697(02)00232-4","article-title":"Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of l-asparaginase in human serum","volume":"309","author":"Lanvers","year":"2002","journal-title":"Anal. Biochem."},{"key":"ref_9","first-page":"478","article-title":"High-throughput asparaginase activity assay in serum of children with leukemia","volume":"6","author":"Fernandez","year":"2013","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/FTD.0000000000001345","article-title":"A Novel Liquid Chromatography\u2013Tandem Mass Spectrometry Method for Monitoring Plasma l-Asparaginase Activity in Pediatric Patients With Acute Lymphoblastic Leukemia Receiving Pegaspargase Treatment","volume":"47","author":"Yu","year":"2025","journal-title":"Ther. Drug Monit."},{"key":"ref_11","unstructured":"(2022). Medical laboratories\u2014Requirements for quality and competence (Standard No. DS\/EN ISO 15189:2022)."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.19.02292","article-title":"Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia","volume":"38","author":"Kloos","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/5\/618\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:25:56Z","timestamp":1779510356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/5\/618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":12,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["pharmaceutics18050618"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18050618","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}